We advised the underwriters on the equity offering

Davis Polk advised the representatives of the several underwriters in connection with the $64.7 million offering of 5,750,000 shares of Jounce Therapeutics, Inc.’s common stock, which includes 750,000 shares from the full exercise of the underwriters’ option to purchase additional shares from the company. The shares of common stock are listed on the Nasdaq Global Select Market under the symbol “JNCE.”

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach.

The Davis Polk capital markets team included partners Deanna L. Kirkpatrick and Yasin Keshvargar and associate Daniel Chao. The tax team included counsel Kiara L. Rankin and associate Eitan Ulmer. Partner David R. Bauer and associate Daniel P. Kearney provided intellectual property advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post